Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Biomarkers Market From 2025 to 2029?

There has been rapid growth in the size of the biomarkers market in the past few years. It is set to expand from $68.77 billion in 2024 to $77.42 billion in 2025, with a compound annual growth rate (CAGR) of 12.6%. The previously observed growth in this sector can be credited to the progress made in genomics and proteomics technologies, the rising occurrence of chronic diseases, the increased focus on personalized medicine, the growing need for companion diagnostics, and the widening scope of applications in drug development.

The biomarkers industry is set for a significant expansion in the coming years, projecting to catapult to “$131.78 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 14.2%.” This anticipated growth for the forecast period is attributable to the increasing emphasis on early detection and prevention of diseases, the broadening inclusion of biomarkers in oncology and immunotherapy, and the increased funding for precision medicine initiatives. Factors like the adoption of liquid biopsy as a non-invasive way to detect biomarkers, and the growing application of biomarkers in drug discovery and development are also contributing to this growth. Key trends expected in this forecast period include the development of panels that utilize multiple biomarkers, the emergence of biomarkers based on exosomes, the widespread use of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the investigation into microbiome-based biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Elements Are Contributing To Growth In The Biomarkers Market?

The rise in heart-related ailments is anticipated to fuel the expansion of the biomarkers market during the predicted timeframe. Thus, the application of biomarkers in treating heart disease patients has seen an exponential rise in recent years. Current practices reveal the natriuretic peptides as the most prevalent biomarker in diagnosing heart failure. Additionally, highly sensitive C-reactive protein, one of the circulating biomarkers, is also employed in diagnosing heart failures. Heart disease remains a leading mortality cause for most racial and ethnic groups in the United States, intensifying the demand for biomarkers. For example, a report from the American College of Cardiology in August 2022 forecasted that all four cardiovascular risk factors in the United States are set to rise between 2025 and 2060. Diabetes is projected to see the most significant leap of 39.3%, affecting 55 million people, followed by dyslipidemia with 27.6% affecting 126 million, hypertension with 25.1% affecting 162 million, and obesity with 18.3% affecting 126 million. Furthermore, the projections also highlighted stroke (33.8% to 15 million) and heart failure (33.4% to 13 million) as the ailments with the most considerable expected increases in rates, followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, these increases in heart diseases and associated fatalities will result in a surge in the growth of the biomarkers market.

Which Segments Are Detailed In The Global Biomarkers Market Report?

The biomarkers market covered in this report is segmented –

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases

3) By Type: Biomarker Of Exposure, Biomarker Of Diseases

4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers

2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers

3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Which Emerging Trends And Strategic Shifts Are Shaping The Biomarkers Market?

Major players in the biomarker sector are zeroing in on building novel solutions, involving ground-breaking biological markers to boost innovation via concerted research, technological incorporation, and rigorous clinical confirmation. A groundbreaking biological marker is a fresh detector that signifies biological procedures and assists in detecting or supervising diseases. It could be a protein, gene, or cellular trait with latent significances for individualized medicine. To illustrate, in September 2024, Genialis, an American computational precision medicine firm, introduced a trailblazing biomarker. This marker, being the first of its kind, escalates the predictive precision for patient responses to KRAS inhibitors. This augmentation aids in delivering customized treatment schedules and enhancing the results of clinical procedures. Its wide-ranging applicability across diverse cancer forms promotes productive drug fabrication and refines patient selection for specific therapies.

Who Are The Key Contributors To Growth In The Biomarkers Market?

Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Which Region Is Projected To Lead The Biomarkers Market By 2025?

North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model